Profound Medical Corp.

NASDAQ•PROF

CEO: Dr. Arun Swarup Menawat MBA, Ph.D.

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2019-10-29

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Contact Information

2400 Skymark Avenue, Unit 6, Mississauga, ON, L4W 5K5, Canada

647-476-1350

www.profoundmedical.com

Market Cap

$156.14M

P/E (TTM)

-3.5

26.5

Dividend Yield

52W High

$8.95

52W Low

$3.76

52W Range

27%

Rank60Top 89.2%

2.1

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.1 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$6.04M+0.00%

4-Quarter Trend

EPS

-$0.37+0.00%

4-Quarter Trend

FCF

-$6.57M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Revenue reached $16.10M USD in 2025, showing 51% growth from $10.68M USD in 2024, driven by recurring sales.

Gross Margin Expansion Gross margin improved to 71% USD in 2025, up from 66% USD in 2024, reflecting better pricing and sales mix.

Successful Capital Raising Secured $40.80M USD net proceeds from December 2025 offerings to fund US commercialization efforts globally.

Cash Position Maintained Ended 2025 with $59.72M USD cash, supported by recent financing activities, ensuring runway for operations.

Risk Factors

Operating Losses Persist Recorded net loss of $42.57M USD in 2025, continuing history of operating losses since inception.

Capital Intensive Business Business requires substantial capital investment for sales expansion and R&D; future financing availability is uncertain.

Market Acceptance Uncertainty Commercial success depends on achieving expected levels of market acceptance for TULSA-PRO system adoption.

Regulatory and IP Challenges Faces risks from complex government regulation, potential IP infringement claims, and evolving compliance requirements globally.

Outlook

Focus on US Commercialization Primary focus remains on expanding TULSA-PRO utilization in the US market through direct sales teams.

Continued R&D Investment Plan to continue product research, development, and clinical studies to support future regulatory approvals internationally.

Strategic Partner Expansion Collaborating with partners like Siemens Healthineers to offer complete MRI-guided prostate therapy solutions.

Peer Comparison

Revenue (TTM)

STIM

$149.16M

+99.2%

OWLT

$105.66M

+35.3%

PRE

$95.11M

+210.6%

Gross Margin (Latest Quarter)

MXCT

92.4%

+16.1pp

SGHT

87.3%

+2.5pp

TLSI

86.7%

-2.8pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CATX	$338.87M	-3.3	-41.3%	0.6%
FBRX	$308.29M	-8.5	-75.6%	0.0%
ARMP	$301.81M	-6.4	70.3%	198.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

32.1%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data